Showing results (131-140 of 143) with videos related to

Sort By:
Pageof 15
World Journal of Urology|May 8, 2015
Optimizing outcome reporting after radical cystectomy for organ-confined urothelial carcinoma of the bladder using oncological trifecta and pentafectaAtiqullah Aziz, Michael Gierth, Michael Rink, et al.
The New England Journal of Medicine|September 16, 2024
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder CancerThomas Powles, James W F Catto, Matthew D Galsky, et al.
European Urology Focus|July 30, 2017
Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks AnalysisMalte W Vetterlein, Thomas Seisen, Matthias May, et al.
World Journal of Urology|February 10, 2015
Risk stratification for locoregional recurrence after radical cystectomy for urothelial carcinoma of the bladderVladimir Novotny, Michael Froehner, Matthias May, et al.
Urologia Internationalis|July 4, 2015
Prediction of Locally Advanced Urothelial Carcinoma of the Bladder Using Clinical Parameters before Radical Cystectomy--A Prospective Multicenter StudyThomas Martini, Atiqullah Aziz, Florian Roghmann, et al.
European Urology|December 17, 2013
Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patientsLuis A Kluth, Malte Rieken, Evanguelos Xylinas, et al.
Cancer Prevention Research (Philadelphia, Pa.)|August 31, 2017
Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder CancerFeng Jin, Jose Thaiparambil, Sri Ramya Donepudi, et al.
European Urology Focus|July 21, 2017
Prognostic Model for Predicting Survival in Patients with Disease Recurrence Following Radical CystectomyLuis A Kluth, Evanguelos Xylinas, Malte Rieken, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2022
Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin ResistanceNiklas Klümper, Damian J Ralser, Jörg Ellinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2024
<i>NECTIN4</i> Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial CancerNiklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, et al.
Pageof 15